Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.

Autor:	Cha-Silva AS; Pfizer, New York, NY., Gavaghan MB; Pfizer, New York, NY., Bergroth T; Pfizer, Stockholm, Sweden., Alexander-Parrish R; Pfizer, New York, NY., Yang J; Pfizer, New York, NY.; Institute for Social and Economic Research and Policy, Columbia University, New York, NY; and., Draica F; Pfizer, New York, NY., Patel J; AESARA, Chapel Hill, NC., Garner DA; AESARA, Chapel Hill, NC., Stanford RH; AESARA, Chapel Hill, NC., Meier G; AESARA, Chapel Hill, NC., McLaughlin JM; Pfizer, New York, NY., Nguyen JL; Pfizer, New York, NY.
Jazyk:	angličtina
Zdroj:	American journal of therapeutics [Am J Ther] 2024 May-Jun 01; Vol. 31 (3), pp. e246-e257. Date of Electronic Publication: 2024 Apr 29.
DOI:	10.1097/MJT.0000000000001744
Abstrakt:	Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high risk of progression to severe disease (eg, hospitalization and death). Despite being the preferred option for outpatient treatment in the majority of countries worldwide, NMV/r is currently underutilized in real-world clinical practice. Areas of Uncertainty: As numerous real-world studies have described patient outcomes following treatment with NMV/r, this systematic literature review provides a comprehensive summary of evidence on NMV/r effectiveness against hospitalization and mortality further organized by clinically meaningful categories, such as acute versus longer-term follow-up, age, underlying health conditions, and vaccination status, to help inform health care decision making. Data Sources: We searched Embase and PubMed (December 22, 2021-March 31, 2023) and congress abstracts (December 1, 2021-December 31, 2022) for reports describing NMV/r effectiveness. Therapeutic Advances: In total, 18 real-world studies met final selection criteria. The evidence showed that NMV/r significantly reduced postinfection risk of all-cause and COVID-19-related hospitalization and mortality in both acute (≤30 days) (21%-92%) and longer-term (>30 days) (1%-61%) follow-up. The reduction in postinfection risk was higher when treatment was received within 5 days of symptom onset. Real-world effectiveness of NMV/r treatment was observed regardless of age, underlying high-risk conditions, and vaccination status. Conclusion: The systematic literature review findings demonstrated the effectiveness of NMV/r against hospitalization and mortality during the Omicron period among individuals at high risk of progression to severe COVID-19 disease. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu